Health
Finerenone limits AFib in patients with chronic kidney disease, Type 2 diabetes – Cardiovascular Business
Treatment with finerenone can help limit new-onset atrial fibrillation (AFib) among patients with chronic kidney disease (CKD) and Type 2 diabetes (T2D), according to new data presented at ACC.21, the American College of Cardiologys 70th annual scientific session.
In the FIDELIO-DKD trial, researchers had already concluded that finerenone, a mineralocorticoid receptor antagonist, reduces the risk of cardiovascular complications in patients with CKD and T2D. This secondary analysis of that same data…
-
Business22 hours agoWhy the Betashares Nasdaq 100 ETF could be a perfect buy and hold pick
-
Noosa News24 hours agoQueensland weather forecast sees sunny weather for last week of winter
-
General18 hours agoMigrants raise concerns over Australia’s English tests for visa applicants
-
Business23 hours agoDoes Macquarie rate BHP shares a buy after its FY25 results?